NeuralCipher Source record
Using caffeine and other adenosine receptor antagonists and agonists as therapeutic tools against neurodegenerative diseases: a review.
DOI: 10.1016/j.lfs.2014.01.083PMID: 24530739
A bibliographic record traceable to Europe PMC.
10.361 articles found
Source record
ABT-089 and ABT-894 reduce levodopa-induced dyskinesias in a monkey model of Parkinson's disease.
DOI: 10.1002/mds.25817PMID: 24515328
A bibliographic record traceable to Europe PMC.
Source record
Primary cultured astrocytes from old rats are capable to activate the Nrf2 response against MPP+ toxicity after tBHQ pretreatment.
DOI: 10.1016/j.neurobiolaging.2014.01.143PMID: 24650792
A bibliographic record traceable to Europe PMC.
Source record
Targeting chelatable iron as a therapeutic modality in Parkinson's disease.
DOI: 10.1089/ars.2013.5593PMID: 24251381
A bibliographic record traceable to Europe PMC.
Source record
Considerations on manganese (Mn) treatments for in vitro studies.
DOI: 10.1016/j.neuro.2014.01.010PMID: 24509086
A bibliographic record traceable to Europe PMC.
Source record
[Triple-gene therapy in Parkinson disease (ProSavin): toward a putaminal dopamine factory?].
DOI: 10.1016/j.neurol.2014.02.002PMID: 24581302
A bibliographic record traceable to Europe PMC.
Open access
Molecular Effects of L-dopa Therapy in Parkinson's Disease.
DOI: 10.2174/1389202914666131210213042PMID: 24653659
A bibliographic record traceable to Europe PMC.
Source record
Current electroconvulsive therapy practice and research in the geriatric population.
DOI: 10.2217/npy.14.3PMID: 24778709
A bibliographic record traceable to Europe PMC.
Open access
Compound Formula Rehmannia alleviates levodopa-induced dyskinesia in Parkinson's disease.
DOI: 10.4103/1673-5374.128246PMID: 25206828
A bibliographic record traceable to Europe PMC.
Source record
Standard strategies for diagnosis and treatment of patients with newly diagnosed Parkinson disease.
DOI: 10.1212/01.cpj.0000444305.61016.0fPMID: 29473592
A bibliographic record traceable to Europe PMC.
Source record
Long-term levodopa/carbidopa intestinal gel in advanced Parkinson's disease.
DOI: 10.1007/s00415-013-7235-1PMID: 24477490
A bibliographic record traceable to Europe PMC.
Source record
Validation of GDI, GPS and GVS for use in Parkinson's disease through evaluation of effects of subthalamic deep brain stimulation and levodopa.
DOI: 10.1016/j.gaitpost.2014.01.011PMID: 24548797
A bibliographic record traceable to Europe PMC.
Records come from scientific sources. Bibliographic counts do not represent completed translations or editorial approvals.